Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Development Endothelin-1/EDNRA transactivation of EGFR


Log In to Post A Comment

Development Endothelin-1/EDNRA transactivation of EGFR

Endothelin-1/EDNRA signaling via EGFR

Endothelin-1, a potent endothelium-derived vasoconstrictor peptide, exerts agrowth-promoting effect on vascular smooth muscle cells, implicating its pathogenic rolein vascular remodeling. Endothelin-1 action is initiated by its binding toEndothelin receptor type A ( EDNRA ) [1], [2].

One of important Endothelin-1/ EDNRA -induced signal pathways isEpidermal growth factor receptor ( EGFR ) transactivation [2], [3], [4]. This pathway may participate in regulation of cell growth,contractility and fibrogenesis in the vascular and muscular tissues [5],[6], [4].

EDNRA is a G-protein coupled receptor [7]. Endothelin-1/EDNRA -induced EGFR transactivation is likely realized via G-proteinalpha-q/11 [8]. A fter ENDRA stimulation by Endothelin-1,G-protein alpha-q/11 dissociates from complex with beta\gamma subunits, and activatePhospholipase C beta ( PLC beta ). PLC beta catalyzes hydrolysis ofphosphatidylinositol 4,5-bisphosphate ( Ptdins(4,5)P2 ) and the generation ofdiacylglycerol ( DAG ) and inositol trisphosphate ( IP3 ) [9],[10]. DAG and IP3 stimulate Protein kinase C, delta (PKC-delta ) and mobilize intracellular Ca('2+), respectively [6].

Activated PKC-delta stimulates Ca('2+) -independent pathway EGFRtransactivation. PKC-delta induces Heparin-binding EGF-like growth factor (HB-EGF ) via cleavage of pro- HB-EGF by matrix metalloproteinase (e.g.,ADAM metallopeptidase domain 9 ( ADAM9 )) and the subsequent release ofHB-EGF, which, in turn, binds to EGFR, leading to EGFR activation[8].

In addition, PKC-delta and Ca('2+) (via intermediate, presumably -Calcium/calmodulin-dependent protein kinase II ( CaMK II )) activate PTK2B proteintyrosine kinase 2 beta ( Pyk2(FAK2) )/ v-src sarcoma (Schmidt-Ruppin A-2) viraloncogene homolog ( c-Src ) complex. c-Src phosphorylates EGFR, thusrealizing Ca('2+) -dependent pathway EGFR transactivation [2].

The activated EGFR provides binding sites for cellular proteins containing Srchomology-2 domain of adaptor proteins, such as SHC (Src homology 2 domain containing)transforming protein 1 ( Shc ) and Growth factor receptor-bound protein 2 (GRB2 ). Both EGFR and Shc are tyrosine phosphorylated byc-Src. Then EGFR and Shc are bound to each other as well asGrb2/ Son of sevenless homologs ( Sos ) complex. Sos catalyzes oconversion of v-Ha-ras Harvey rat sarcoma viral oncogene homolog ( H-Ras ) fromGDP- to GTP-form. H-Ras -GTP is then able to bind to and activate v-raf-1 murineleukemia viral oncogene homolog 1 ( c-Raf-1 )/ Mitogen-activated protein kinasekinases 1 and 2 ( MEK1(MAP2K1) and MEK2(MAP2K2) )/ Mitogen activatedprotein kinases 3 and 1 ( ERK1/2) ) cascade [2], [11],[12].

Endothelin-1/ EDNRA/ EGFR -activated ERK1/2 participatesin remodeling/fibrosis of vascular and muscular tissues (possibly, via activator oftranscription Collagen I via Signal transducer and activator of transcription 5 (STAT5 )/ Sp1 transcription factor ( SP1 ) [5], [6], [13].

In addition, ERK1/2 may stimulate expression of transcription factor v-fos FBJmurine osteosarcoma viral oncogene homolog ( c-Fos ) [8] (e.g., viaSP1 ), thus activating cell growth and proliferation.

Moreover, ERK1/2 activated via Endothelin-1/ EDNRACa('2+) -dependent EGFR transactivation, may phosphorylate Ribosomalprotein S6 kinase, 70kDa, polypeptide 2 ( p70 S6 kinase 2), which plays acritical role in progression of cell cycle and translation [2].

Endothelin-1/ EDNRA -induced EGFR activates Phosphatidylinositol3 kinase ( PI3K )/ v-akt murine thymoma viral oncogene homolog 1 (AKT(PKB) ) pathway. PI3K/ AKT(PKB) may stimulate Ca('2+)uptake (e.g., via Calcium channels, voltage-dependent, L type ( L-type Ca(II)channel )) [4]. In addition, PI3K/ AKT(PKB) pathway maystimulate FK506 binding protein 12-rapamycin associated protein 1 ( mTOR ), whichactivates Ribosomal protein S6 kinase, 70kDa, polypeptide 1 ( p70 S6 kinases 1 )and p70 S6 kinase 2 [2], [14]. Thus, PI3K/AKT(PKB) pathway may participate in progression of cell cycle and translation.